CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1

AIDS

Volumn 21, Issue 10, 2007, Pages 1317-1322

  Heredia, Alonso ^a   Gilliam, Bruce ^a   DeVico, Anthony ^a   Le, Nhut ^a   Bamba, Douty ^a   Flinko, Robin ^a   Lewis, George ^a   Gallo, Robert C ^a   Redfield, Robert R ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

Antiretroviral therapy; CCR5; Coreceptor; Enfuvirtide; Fusion inhibitors

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR DENSITY; STATISTICAL SIGNIFICANCE; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; VIRUS REPLICATION;

EID: 34249989936     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32815278ea     Document Type: Article

References (30)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958.
2. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-666.
3. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4R cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
4. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-877.
5. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3:338-340.
6. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
7. Hladik F, Lentz G, Delpit E, McElroy A, McElrath MJ. Coexpression of CCR5 and IL-2 in human genital but not blood T cells: implications for the ontogeny of the CCR5R Th1 phenotype. J Immunol 1999; 163:2306-2313.
8. Hladik F, Liu H, Speelmon E, Livingston-Rosanoff D, Wilson S, Sakchalathorn P, et al. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005; 79:11677-11684.
9. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96:5215-5220.
10. Reynes J, Portales P, Segondy M, Baillat V, Andre P, Reant B, et al. CD4RT cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis 2000; 181:927-932.
11. Reynes J, Portales P, Segondy M, Baillat V, Andre P, Avinens O, et al. CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 2001; 15:1627-1634.
12. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-2864.
13. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99:16249-16254.
14. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, et al. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 2004; 78:5476-5485.
15. Platt EJ, Durnin JP, Kabat D. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J Virol 2005; 79:4347-4356.
16. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM, et al. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998; 72:7450-7458.
17. Kinter AL, Poli G, Fox L, Hardy E, Fauci AS. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995; 154:2448-2459.
18. Salkowitz JR, Bruse SE, Meyerson H, Valdez H, Mosier DE, Harding CV, et al. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol 2003; 108:234-240.
19. Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses 2003; 19:177-186.
20. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997; 94:1925-1930.
21. Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5:276-279.
22. Kliger Y, Shai Y. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol 2000; 295:163-168.
23. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151:413-423.
24. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75:8605-8614.
25. Choudhry V, Zhang MY, Harris I, Sidorov IA, Vu B, Dimitrov AS, et al. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 2006; 348:1107-1115.
26. Doranz BJ, Baik SS, Doms RW. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J Virol 1999; 73:10346-10358.
27. Doranz BJ, Orsini MJ, Turner JD, Hoffman TL, Berson JF, Hoxie JA, et al. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions. J Virol 1999; 73:2752-2761.
28. Hoffman TL, Canziani G, Jia L, Rucker J, Doms RW. A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors. Proc Natl Acad Sci USA 2000; 97:11215-11220.
29. Yuan W, Craig S, Si Z, Farzan M, Sodroski J. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol 2004; 78:5448-5457.
30. Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002; 46:1336-1339.